The short version of GHRH analogue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
A pariah field, cast out by the scientific establishment. Between cold fusion and respectable science there is virtually no communication at all. Cold fusion papers are almost never published in refereed scientific journals, with the result that those works don't receive the normal critical scrutiny that science requires. On the other hand, because the Cold-Fusioners see themselves as a community under siege, there is little internal criticism. Experiments and theories tend to be accepted at face value, for fear of providing even more fuel for external critics, if anyone outside the group was bothering to listen. In these circumstances, crackpots flourish, making matters worse for those who believe that there is serious science going on here.
=== Critical reception === In New Statesman, Fergal Kinney described Logan as "television's first truly irredeemable leading man," lauding him as a malevolent, ruthless figure rather than a sympathetic anti-hero. Kinney contrasted Logan's actions from Tony Soprano, Walter White, Don Draper, and Omar Little as fundamentally repulsive, receiving no redemption for his dark actions that lead to climate change, civilian death, and mass exploitation. Emily St. James of Vox noted that the monstrosity of Logan's character is critical to the formation of his children, emphasizing how "all they have known is damage." Cox's performances in multiple episodes were singled out as highlights. In an AV Club review of the episode "Which Side Are You On?", Cox's portrayal of Logan is described as "Trumpian" and "steals the scene." The humiliating game that Logan forces his family to play in "Hunting" has been described as "terrifying" and embelic of his character's cruelty. Cox's penultimate appearance in the series in "Rehearsal" was acclaimed by TVLine as both "summon[ing] a formidable energy" and "revealing just the slightest hint of vulnerability." Many critics drew comparisons between Logan and the Shakespearean character of King Lear. Obvious similarities between Logan and Lear include them both dividing their possessions to their three children, the siblings being forced to demonstrate their devotion to their father, and the mutual destruction that becomes of their entire family.
In general, the reference range (that found in healthy young persons), is about 30–33 mmol/mol (4.9–5.2 DCCT %). The mean HbA1c for diabetics type 1 in Sweden in 2014 was 63 mmol/mol (7.9 DCCT%) and for type 2, 61 mmol/mol (7.7 DCCT%). HbA1c levels show a small, but statistically significant, progressive uptick with age; the clinical importance of this increase is unclear. A study indicated that it is possible to predict HbA1c values years in advance, by analyzing blood glucose patterns measured using continuous glucose monitors
=== Post-translational modification === Additionally, the protein can undergo a variety of post-translational modifications, which are briefly summarized here. The N-terminal amino group of a polypeptide can be modified covalently, e.g.,
Sources: en.wikipedia.org
There is a risk of misuse and dependence in both patients and non-medical users of alprazolam; alprazolam's high affinity binding, high potency, and rapid onset increase its abuse potential. The physical dependence and withdrawal syndrome of alprazolam also add to its addictive nature. In the small subgroup of individuals who escalate their doses, there is usually a history of alcohol or other substance use disorders. Despite this, most prescribed alprazolam users do not use their medication recreationally, and the long-term use of benzodiazepines does not generally correlate with the need for dose escalation. However, based on US findings from the Treatment Episode Data Set (TEDS), an annual compilation of patient characteristics in substance abuse treatment facilities in the United States, admissions due to "primary tranquilizer" (including, but not limited to, benzodiazepine-type) drug use increased 79% from 1992 to 2002, suggesting that misuse of benzodiazepines may be on the rise. The Centers for Disease Control and Prevention (CDC) reported an 89 percent increase in emergency room visits nationwide related to nonmedical benzodiazepine use between 2004 and 2008. Alprazolam is one of the most commonly prescribed and misused benzodiazepines in the United States. A large-scale nationwide U.S.
=== Receptor-mediated permabilitizers === These are drug compounds that increase the permeability of the blood–brain barrier. By decreasing the restrictiveness of the barrier, it is much easier to get a molecule to pass through it. These drugs increase the permeability of the blood–brain barrier temporarily by increasing the osmotic pressure in the blood which loosens the tight junctions between the endothelial cells. By loosening the tight junctions normal injection of drugs through an [IV] can take place and be effective to enter the brain. This must be done in a very controlled environment because of the risk associated with these drugs. Firstly, the brain can be flooded with molecules that are floating through the blood stream that are usually blocked by the barrier. Secondly, when the tight junctions loosen, the homeostasis of the brain can also be thrown off which can result in seizures and the compromised function of the brain.
Grades from four quarters of 7th grade and the first quarter of 8th grade (or four quarters of 8th grade and first quarter of 9th grade) in math, science, English, and social studies A standardized reading comprehension test A standardized numerical test All of these are factored into a final score. The number of students admitted into the S/T program vary from each school, but as an example, 225-250 students with the top scores are admitted to Roosevelt's Science and Technology Program. The next 60 students are placed on a waiting list. All interested 8th and 9th grade students who are residents of Prince George's County are eligible to apply for admission to the Science and Technology Center.
=== Development === The project started with producer Mace Neufeld, and was intended as a prestige thriller headlined by James Caan but that version stalled due to difficulties with the script. Neufeld later partnered with Moshe Diamant to pitch it, under the title Heart of Stone, to football player and aspiring actor Brian Bosworth. Diamant's Epic Productions had formed a joint venture with Michael Douglas and Rick Bieber's Stonebridge Entertainment called the Stone Group and the Douglas connection was an added incentive to Bosworth. Joining the other executive producers was Gary Wichard, Bosworth's personal manager who had spearheaded his transition to movies. Producer duties were entrusted to Yoram Ben Ami, CEO of Triumph Releasing, a Columbia Pictures subsidiary that usually dealt with Diamant's product. During pre-production, the screenplay was attributed to Walter Doninger and Howard Cushnir (the latter is absent from the final credits). It was retooled for Bosworth, who consulted with the writers over about one year. A late pre-production report claimed that the story was to be set in the Midwest. However, Ben Ami indicated that the Deep South region had been chosen because it was in the script, and some of the eventual locations had been in talks to host since at least summer 1989.
The states of the Federal Republic of Germany, and so Lower Saxony, have legislative responsibility and power mainly reduced to the policy fields of the school system, higher education, culture and media and police, while other policy fields like economic and social policies, foreign policy are a prerogative of the federal government. Hence the probably most important function of the federal states is their representation in the Federal Council (Bundesrat), where their approval on many crucial federal policy fields, including the tax system, is required for laws to become enacted.
Sources: en.wikipedia.org
=== Marketed === Daridorexant (nemorexant; Quviviq) – dual OX1 and OX2 antagonist – approved for insomnia in January 2022, formerly under development for sleep apnea – half-life 8 hours Fazamorexant (Mengping) – dual OX1 and OX2 antagonist – approved for insomnia in China in May 2026 – half-life 2–4 hours Lemborexant (Dayvigo) – dual OX1 and OX2 antagonist – approved for insomnia in December 2019 and released June 1 2020, under development for circadian rhythm sleep disorders, chronic obstructive pulmonary disease, and sleep apnea – half-life 17–55 hours Suvorexant (Belsomra) – dual OX1 and OX2 antagonist – approved for insomnia in August 2014, under development for delirium – half-life 12 hours Vornorexant (Vorzzz) – dual OX1 and OX2 antagonist – approved for insomnia in Japan in August 2025 – half-life 1.5–3 hours
Methylenedioxypyrovalerone (MDPV) is a psychoactive drug with stimulant properties that acts as a norepinephrine–dopamine reuptake inhibitor (NDRI). It was first developed in the 1960s by a team at Boehringer Ingelheim. MDPV remained an obscure stimulant until around 2004, when it was reported to be sold as a designer drug. Products labeled as bath salts containing MDPV were previously sold as recreational drugs in gas stations and convenience stores in the United States, similar to the marketing for spice and K2 as incense. Incidents of psychological and physical harm have been attributed to MDPV use.
== Definition == Per United States legislation, the Dietary Supplement Health and Education Act of 1994 provided the following definition of dietary supplements: "The Dietary Supplement Health and Education Act of 1994 (DSHEA) defines the term "dietary supplement" to mean a product ... intended to supplement the diet that bears or contains one or more of the following dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary substance for use by man to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or combination of any of the aforementioned ingredients. Furthermore, a dietary supplement must be labeled as a dietary supplement and be intended for ingestion and must not be represented for use as conventional food or as a sole item of a meal or of the diet. In addition, a dietary supplement cannot be approved or authorized for investigation as a new drug, antibiotic, or biologic, unless it was marketed as a food or a dietary supplement before such approval or authorization. Under DSHEA, dietary supplements are deemed to be food, except for purposes of the drug definition." Per DSHEA, dietary supplements are consumed orally, and are mainly defined by what they are not: conventional foods (including meal replacements), medical foods, preservatives, or pharmaceutical drugs. Products intended for use as a nasal spray or topical application, such as a lotion applied to the skin, do not qualify. FDA-approved drugs cannot be ingredients in dietary supplements.
=== Pharmacokinetics === Ketamine can be absorbed by many different routes due to its water and lipid solubility. Intravenous ketamine bioavailability is 100% by definition, intramuscular injection bioavailability is slightly lower at 93%, and epidural bioavailability is 77%. Subcutaneous bioavailability has never been measured but is presumed to be high. Among the less invasive routes, the intranasal route has the highest bioavailability (45–50%) and oral – the lowest (16–20%). Sublingual and rectal bioavailabilities are intermediate at approximately 25–50%. After absorption ketamine is rapidly distributed into the brain and other tissues. The plasma protein binding of ketamine is variable at 23–47%.
release of pituitary hormones synthesis of pituitary hormones release of stored pituitary hormones hyperplasia hypertrophy The anterior pituitary produces prolactin, GH, TSH, ACTH, FSH, and LH. Fifteen to 20 percent of corticotroph cells produce ACTH. The targets are the adrenal glands, adipocytes and melanocytes. Three to five percent of thyrotroph cells produce TSH. Ten to 15 percent are gonadotrophic and produce LH and FSH. Forty to 50 percent are somatotrophic and produce GH, in childhood in particular. Ten to 15 percent are lactotrophic and produce prolactin.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.